Welcome to our dedicated page for Black Diamond Therapeutics SEC filings (Ticker: BDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Black Diamond Therapeutics filings document financial results, clinical-program disclosures and governance matters for a Nasdaq-listed clinical-stage oncology company. Recent Form 8-K reports furnish quarterly and annual operating results and corporate updates tied to silevertinib, the company’s EGFR MasterKey inhibitor program for EGFR-mutant NSCLC and glioblastoma, along with liquidity and capital-expenditure commentary.
Proxy materials disclose annual meeting matters, including board-class elections, auditor ratification, advisory executive-compensation votes and the preferred frequency of future compensation votes. The filings also identify the company’s registered common stock, par value and Nasdaq Global Select Market listing under the BDTX symbol.
Black Diamond Therapeutics is a clinical-stage oncology company focused on MasterKey therapies such as silevertinib, a fourth-generation EGFR inhibitor for EGFR‑mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM). For the quarter ended June 30, 2026, it reported a net loss of $9.9 million, or $0.17 per share, versus a $10.6 million loss a year earlier. Six-month results shifted from prior-year net income of $46.0 million, which had included a $70.0 million Servier upfront payment, to a net loss of $18.9 million.
Research and development expense declined to $7.4 million in the quarter and $14.4 million year-to-date, reflecting lower spending on the NSCLC Phase 2 trial and the out-licensed BDTX‑4933 program, partly offset by start-up costs for a Phase 2 GBM trial. General and administrative expense was $4.7 million in the quarter and $8.9 million for six months. Cash, cash equivalents and investments totaled about $110.5 million, with total assets of $125.0 million and stockholders’ equity of $96.1 million, and management currently expects this liquidity to fund operations into the second half of 2028. The Servier license for BDTX‑4933 provides potential milestones of up to $710.0 million plus tiered royalties, while the company also has an at-the-market equity program that has raised $25.0 million gross to date.
Black Diamond Therapeutics reported second-quarter 2026 results and highlighted new Phase 2 data for silevertinib in frontline non-classical EGFR-mutant NSCLC. At an April 11, 2026 cutoff, silevertinib showed an Objective Response Rate of 60%, CNS ORR of 86%, Disease Control Rate of 91%, preliminary median progression-free survival of 15.2 months, and no de novo brain metastases, with data supporting a 150 mg once-daily dose for pivotal development.
The company plans Phase 2 trial and FDA feedback updates in the fourth quarter of 2026 and is advancing a Phase 2 GBM combination study. Cash, cash equivalents, and investments were $110.5 million as of June 30, 2026, which is expected to fund operations into the second half of 2028. Second-quarter 2026 R&D expenses were $7.4 million (down from $9.3 million a year earlier), G&A expenses were $4.7 million (up from $4.1 million), net loss was $9.9 million (vs. $10.6 million), and net cash used in operations was $8.0 million (vs. $9.2 million).
BlackRock, Inc. reports beneficial ownership of 3,838,590 shares of Black Diamond Therapeutics, Inc. common stock on a Schedule 13G, representing 6.7% of the class. BlackRock has sole voting power over 3,806,227 shares and sole dispositive power over 3,838,590 shares, with no shared voting or dispositive power. The filing explains that these holdings are attributed to certain BlackRock business units, and that various underlying clients have rights to dividends or sale proceeds, but no single person has an interest in more than five percent of Black Diamond’s outstanding common shares.
T. Rowe Price Investment Management, Inc. amended its Schedule 13G/A to report beneficial ownership of 4,028,202 shares of Black Diamond Therapeutics I common stock, representing 7.0% of the class as of 06/30/2026. The filing lists 3,992,774 shares as sole voting power and 4,028,202 as sole dispositive power. The filing also includes a statement that the filer "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
Black Diamond Therapeutics director Ali Behbahani received a grant of stock options covering 40,000 shares of common stock at an exercise price of $1.71 per share. The options expire on June 25, 2036 and were granted as a compensation award, not an open-market purchase.
According to the terms, all 40,000 options will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Behbahani continues to serve as a director through that date. After this grant, his directly held option position reported in this filing totals 40,000 options.
Black Diamond Therapeutics director Samarth Kulkarni received a grant of stock options covering 40,000 shares of common stock. These options have an exercise price of $1.71 per share and are held directly in his name.
The options vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve through that vesting date. After this grant, he holds options to acquire 40,000 shares, and there are no open-market purchases or sales reported in this filing.
Black Diamond Therapeutics director Garry E. Menzel received a stock option award for 40,000 shares of common stock. The option has an exercise price of $1.71 per share and expires on June 25, 2036. It was granted as a compensation award rather than a market purchase or sale.
The option will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, subject to his continued service through that date. Following this grant, he holds 40,000 option-based rights directly.
Black Diamond Therapeutics director Raman Prakash received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036. Following this grant, Prakash holds options for 40,000 underlying shares.
According to the vesting terms, the options will become fully exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve the company through that vesting date.
Black Diamond Therapeutics director Kapil Dhingra received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036. All 40,000 options are reported as held directly following this award.
According to the grant terms, the options will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Dhingra continues to serve through the vesting date. This is a compensation-related award, not an open-market purchase.
Black Diamond Therapeutics director Shannon Campbell received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036.
According to the terms, the entire option grant will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Campbell continues to serve through that date. Following this grant, Campbell holds options for 40,000 underlying shares directly.